Amyloid and Alzheimer’s disease

References

[1] Amijee, H., and Scopes, D.I.C. (2009). The quest for small molecules as amyloid inhibiting therapies for Alzheimer’s disease. J Alzheimers Dis 17, 33-47 .
[2] Buckingham, S.D., Jones, A.K., Brown, L.A., and Sattelle, D.B. (2009). Nicotinic acetylcholine receptor signalling: roles in Alzheimer’s disease and amyloid neuroprotection. Pharmacol Rev 61, 39-61 .10.1124/pr.108.000562
[3] Cahill, C.M., Lahiri, D.K., Huang, X.D., and Rogers, J.T. (2009). Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochimica Et Biophysica Acta-General Subjects 1790, 615-628 .10.1016/j.bbagen.2008.12.001
[4] F?ndrich, M., Meinhardt, J., and Grigorieff, N. (2009). Structural polymorphism of Alzheimer Abeta and other amyloid fibrils. Prion 3, 89-93 .
[5] Jacobsen, K.T., and Iverfeldt, K. (2009). Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors. Cell Mol Life Sci 66, 2299-2318 .10.1007/s00018-009-0020-8
[6] Kaminsky, Y.G., Marlatt, M.W., Smith, M.A., and Kosenko, E.A. (2010). Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35). Exp Neurol 221, 26-37 .10.1016/j.expneurol.2009.09.005
[7] Kawahara, M., Negishi-Kato, M., and Sadakane, Y. (2009). Calcium dyshomeostasis and neurotoxicity of Alzheimer’s beta-amyloid protein. Expert Rev Neurother 9, 681-693 .10.1586/ern.09.28
[8] Langkilde, A.E., and Vestergaard, B. (2009). Methods for structural characterization of prefibrillar intermediates and amyloid fibrils. FEBS Lett 583, 2600-2609 .10.1016/j.febslet.2009.05.040
[9] Lei, H., Wu, C., Wang, Z., and Duan, Y. (2006). Molecular dynamics simulations and free energy analyses on the dimer formation of an amyloidogenic heptapeptide from human beta2-microglobulin: implication for the protofibril structure. J Mol Biol 356, 1049-1063 .10.1016/j.jmb.2005.11.087
[10] Lührs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., D?beli, H., Schubert, D., and Riek, R. (2005). 3D structure of Alzheimer’s amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A 102, 17342-17347 .10.1073/pnas.0506723102
[11] Normando, E.M., Coxon, K.M., Guo, L., and Cordeiro, M.F. (2009). Focus on: amyloid beta. Exp Eye Res 89, 446-447 .10.1016/j.exer.2009.05.004
[12] Origlia, N., Arancio, O., Domenici, L., and Yan, S.S. (2009). MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE. Expert Rev Neurother 9, 1635-1645 .10.1586/ern.09.107
[13] Pahnke, J., Walker, L.C., Scheffler, K., and Krohn, M. (2009). Alzheimer’s disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression? Neurosci Biobehav Rev 33, 1099-1108 .10.1016/j.neubiorev.2009.05.006
[14] Petkova, A.T., Ishii, Y., Balbach, J.J., Antzutkin, O.N., Leapman, R.D., Delaglio, F., and Tycko, R. (2002). A structural model for Alzheimer’s beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 99, 16742-16747 .10.1073/pnas.262663499
[15] Pimplikar, S.W. (2009). Reassessing the amyloid cascade hypothesis of Alzheimer’s disease. Int J Biochem Cell Biol 41, 1261-1268 .10.1016/j.biocel.2008.12.015
[16] Tabaton, M., Zhu, X.W., Perry, G., Smith, M.A., and Giliberto, L. (2010). Signaling effect of amyloid-beta(42) on the processing of AbetaPP. Exp Neurol 221, 18-25 .10.1016/j.expneurol.2009.09.002
[17] Tompa, P. (2009). Structural disorder in amyloid fibrils: its implication in dynamic interactions of proteins. FEBS J 276, 5406-5415 .10.1111/j.1742-4658.2009.07250.x
[18] T?r?k, M., Milton, S., Kayed, R., Wu, P., McIntire, T., Glabe, C.G., and Langen, R. (2002). Structural and dynamic features of Alzheimer’s Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem 277, 40810-40815 .10.1074/jbc.M205659200